MAPAM

Mapping the Gut Microbiome (MAPAM) is a biotechnology company focused on uncovering novel therapeutic chemical space within the human gut microbiome. The company utilizes a proprietary platform that combines genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop small molecule therapeutics for challenging immunologic disorders. By building an extensive gut-DNA atlas, MAPAM aims to access the "dark matter" of microbial DNA to discover viable drug candidates. Their streamlined workflow integrates multi-omic data with high-throughput phenotypic screening to accelerate the transition from target discovery to clinical validation.